AstraZeneca Symbicort (budesonide/formoterol) by Year

Name: AstraZeneca Symbicort (budesonide/formoterol) by Year (AZN)
Creator: AstraZeneca

Symbicort (budesonide/formoterol) — Worldwide product sales ($M) ($M)

Quarterly Annual

AstraZeneca Symbicort (budesonide/formoterol): $2,885M in FY2025, up 0.2% from a year earlier.

Latest, FY2025

2,885

Period ended Dec 31, 2025

Change on a year earlier

+0.2%

2,879 in FY2024

History

10 years

Since FY2016

Sources

Documents cited below

Where the FY2025 figure comes from

“|| Symbicort | 2,885 | - | - | 1,193 | 1 | 801 | (1) | 1 | 560 | - | (3) | 331 | 1 | 3”

Source: Form 6-K FY2025Q4 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Symbicort (budesonide/formoterol) — Worldwide product sales ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	2,885	+0.2%	Form 6-K FY2025Q4 Earnings Release ↗
FY2024	Dec 31, 2024	2,879	+21.9%	Form 6-K FY2024Q4 Earnings Release ↗
FY2023	Dec 31, 2023	2,362	-6.9%	Form 6-K FY2023Q4 Earnings Release ↗
FY2022	Dec 31, 2022	2,538	-7.0%	Form 6-K FY2022Q4 Earnings Release ↗
FY2021	Dec 31, 2021	2,728	+0.3%	Form 6-K FY2021Q4 Earnings Release ↗
FY2020	Dec 31, 2020	2,721	+9.1%	Form 6-K FY2020Q4 Earnings Release ↗
FY2019	Dec 31, 2019	2,495	-2.6%	Form 20-F (filed 2020-03-03) ↗
FY2018	Dec 31, 2018	2,561	-8.6%	Form 20-F (filed 2019-03-05) ↗
FY2017	Dec 31, 2017	2,803	-6.2%	Form 20-F (filed 2019-03-05) ↗
FY2016	Dec 31, 2016	2,989	–	Form 20-F (filed 2019-03-05) ↗

Breakdown

What makes up symbicort (budesonide/formoterol)

Cite this data

StockData. (2026). AstraZeneca Symbicort (budesonide/formoterol) ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-symbicort-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.